Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Longevity
Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis.
Peptide B
Longevity
Central cellular cofactor — supplemented to support mitochondrial function and sirtuin activity.
Typical vial
5 mg
Typical dose
5000-10000 mcg
Half-life
Not well characterized in humans (estimated hours based on peptide size)
FDA status
Not FDA approved. Investigational compound with no clinical …
Typical vial
500 mg
Typical dose
50-200 mg (SubQ); 500-1500 mg (IV) mcg
Half-life
~6-10 hours (cellular turnover)
FDA status
Not FDA approved as a therapeutic. Available via compounding…
MOTS-c effects
NAD+ (Injectable) effects
MOTS-c side effects
NAD+ (Injectable) side effects
MOTS-c dosing ranges
Metabolic optimization and longevity
5-10 mg · Three to five times weekly (SubQ) · 4-8 weeks
NAD+ (Injectable) dosing ranges
IV anti-aging clinic protocol
500-1500 mg · Per infusion, weekly to monthly · Cycle-based
Subcutaneous wellness
50-200 mg · Daily or alternate-day · 2-4 week cycles
Intranasal
20-100 mg · Daily · Cycle-based
MOTS-c: Mitochondrial-derived peptide that mimics exercise and regulates metabolic homeostasis. Typical dose 5000-10000 mcg. NAD+ (Injectable): Central cellular cofactor — supplemented to support mitochondrial function and sirtuin activity. Typical dose 50-200 mg (SubQ); 500-1500 mg (IV) mcg. Both fall under the Longevity category.
Stacking MOTS-c with NAD+ (Injectable) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
MOTS-c is typically dosed: Three to five times weekly (SubQ) for Metabolic optimization and longevity. NAD+ (Injectable) is typically dosed: Per infusion, weekly to monthly for IV anti-aging clinic protocol; Daily or alternate-day for Subcutaneous wellness; Daily for Intranasal.
MOTS-c: Not FDA approved. Investigational compound with no clinical trials completed for regulatory submission. NAD+ (Injectable): Not FDA approved as a therapeutic. Available via compounding pharmacies for off-label use. NAD+ precursors (NR as Niagen, NMN) sold as dietary supplements.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free